Progress in the treatment of chronic lymphocytic leukaemia - European Medical Journal

Progress in the treatment of chronic lymphocytic leukaemia

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses new agents, with different mechanisms of action and in different stages of clinical development, for the treatment of patients with chronic lymphocytic leukaemia (CLL). These include the immunomodulatory agent, lenalidomide, for untreated CLL; the Bruton’s tyrosine kinase inhibitor, ibrutinib, for previously treated CLL; and the monoclonal anti-CD20 antibody, rituximab, for older patients with previously untreated CLL.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>